Pooled in Vivo Screens for Cancer Immunotherapy Target Discovery

[...]we recovered molecules that are currently under development as immunotherapy targets. Because only the tumor cells are genetically perturbed in the experiment, it can only be used to directly query biology that is specific to genes expressed by tumor cells. Since current immune checkpoint inhib...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2018-03, Vol.10 (3), p.167-170
Main Authors: Lane-Reticker, Sarah K, Manguso, Robert T, Haining, W Nicholas
Format: Article
Language:English
Subjects:
Antigens
Breast
Breast cancer
Cancer
Cancer immunotherapy
Clinical trials
CRISPR
CTLA-4 protein
Genes
Genetic screening
Genomes
Genomics
Immune checkpoint inhibitors
Immune system
Immunotherapy
Lymphocytes
Melanoma
Metastasis
Mutation
Pancreatic cancer
PD-1 protein
Solid tumors
Synergism
Tumor cells
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]we recovered molecules that are currently under development as immunotherapy targets. Because only the tumor cells are genetically perturbed in the experiment, it can only be used to directly query biology that is specific to genes expressed by tumor cells. Since current immune checkpoint inhibitors have only shown efficacy in a subset of solid tumors, screens in additional cell types such as breast or pancreatic cancer could offer insight into mechanisms of immunotherapy resistance or sensitivity in tumors that are not responsive to currently approved immunotherapy options. Furthermore, screening for genes that synergize or cause resistance specifically to CTLA-4, PD-1 and CTLA-4 combination therapy, or any of the other immunotherapies currently in development could allow for comparison of the genes involved in tumor responses mediated by different components of the immune system. Because these therapies work through distinct mechanisms (14), our screening method could help further identify the pathways associated with sensitivity or resistance to each immunotherapy.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2017-0164